Table of Content


Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Cancer Vaccine dealmaking
2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 – Leading Cancer Vaccine deals
3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 – Most active Cancer Vaccine dealmakers
4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 – Cancer Vaccine contracts dealmaking directory
5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 – Cancer Vaccine dealmaking by technology type

Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Cancer Vaccine deals by company A-Z

Appendix 2 – Cancer Vaccine deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 – Cancer Vaccine deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 – Cancer Vaccine deals by therapy area

Appendix 5 –Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cancer Vaccine partnering since 2010
Figure 2: Active Cancer Vaccine dealmaking activity since 2010
Figure 3: Cancer Vaccine partnering by deal type since 2010
Figure 4: Cancer Vaccine partnering by disease type since 2010
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2010
Figure 10: Most active Cancer Vaccine dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events